Fig. 4
From: Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell
Cytolytic activity of VEGFR2-CAR T cells with either a long or a short extracellular spacer domain. (A) The panel shows CD107a expression on CD3 + T cells from a representative donor transduced with mock, and long- and short-spacer-containing CAR constructs. (B) Data from two individual donors in two different experimental environments. The CD107a expression was significantly higher in the case of long spacer CAR (64.4 ± 3.8%) compared with short spacer CAR (40.5 ± 3.3%), p < 0.05. (C) CFSE/PI cytotoxicity assay of short and long spacer VEGFR2-CAR T cells at E:T ratios of 3:1 (35 ± 3.2% vs. 21.5 ± 2.4%, respectively) and 1:1 (both 20%) after co-culturing of CAR T cells with VEGFR2 + cells (***p < 0.001, **p < 0.01)